MEDS

Corexa Health's three divisions - pharmacy, distribution, and tech & hub - positioned to serve the emerging compounded peptide market TAMPA, FL / ACCESS Newswire / October 16, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its super intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, today applauded the issuance of a new policy proposal by the U.S. Food and Drug Administration (FDA) entitled "Interim Access Policy for Compounding Using Certain Peptides." The new proposed policy comes less than three months following the

Platform to be integrated into Health Lives Here app as a subscription offering TAMPA, FL / ACCESS Newswire / October 14, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its super intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, today announced that it has entered into an exclusive license, revenue sharing and marketing agreement with REBOOT Health AI, Inc. ("REBOOT") for Direct-to-Consumer (DTC) rights in the United States to REBOOT's proprietary care management platform. The Companies will work together to tailor th

Leading Health IT Company has Implemented Cost Control Measures and Refocused Remaining Workforce Towards ChemoFx® Commercialization with Hospital Systems, HMOs, GPOs and Cancer Centers TAMPA, FL / ACCESS Newswire / October 13, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its super intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, today announced that it has implemented cost control measures, primarily through reductions in corporate management positions, to focus the workforce spend on commercializing ChemoFx® as a

Humana adds ChemoFx® to its Medicaid Pharmacogenomics Testing coverage policy TAMPA, FL / ACCESS Newswire / October 12, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company vertically integrating its Health IT and physical infrastructure together with its super intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, today announced that its recently acquired CLIA-certified precision oncology laboratory subsidiary Helomics Corporation has received a Medicaid coverage determination in gynecologic cancers for the ChemoFx® Assay, a commercially available chemoresponse test that measures how a patien

Healthcare IT Company and its Subsidiary Undertake Action Following US Government's Updated Nomenclature TAMPA, FL / ACCESS Newswire / October 5, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its artificial intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, today announced that it has filed DBAs for 'DataMEDS SI' and 'Corexa Health SI'. The Company also reminded shareholders of record as of the close of business on August 7, 2026 (the "Record Date") that the previously announced distribution (the "Distribution") of Dr

DENVER, Oct. 01, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – The markets are charging into October with a wave of fresh milestones and potential catalysts, putting Nexalin Technology (NASDAQ:NXL), Kraig Biocraft Laboratories (OTCQB:KBLB), Veea (NASDAQ:VEEA), and DataMeds AI (NASDAQ:MEDS) firmly in the market spotlight. Nexalin Technology Targets South America with 10-Year Commercial Push Nexalin Technology (NASDAQ:NXL) has turned what was previously a Brazil-focused commercialization effort into a much broader South American expansion story. On October 1, the company announced a definitive exclusive distribution and local-manufacturing agreement with Inovanexa Medical Technologies cov

September 2026 revenue up more than 66 percent from July 2026 with expansion of retail customer base and Tollo Health pharmaceutical-adjunct product launches TAMPA, FL / ACCESS Newswire / October 1, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its artificial intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, today provided a revenue update on Corexa Pharmacy, a division of its wholly owned subsidiary Corexa Health.Corexa Pharmacy recorded preliminary, unaudited revenue of more than $1 million for September 2026, an increase of more

DENVER, Sept. 28, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- Kodiak Sciences (NASDAQ:KOD), NeOnc Technologies Holdings (NASDAQ:NTHI), DataMeds AI (NASDAQ:MEDS), and KNOREX (NYSEAMERICAN:KNRX) are each approaching important milestones that could reshape how investors view their pipelines, platforms and near-term prospects. Kodiak Sciences: Five Phase 3 Wins Put Zenkuda on the Regulatory Runway Kodiak Sciences (NASDAQ:KOD) delivered one of the biggest clinical updates in the group. Its pivotal Phase 3 DAYBREAK study produced positive primary-endpoint results for both Zenkuda and tabirafusp-ted in wet age-related macular degeneration. Zenkuda achieved non-inferiority to aflibercept on

Healthcare IT Company and Nutritional Products Maker to Work with NFL Alumni Health to Drive Awareness of GLP-1 Telehealth and Pharmacy Services TAMPA, FL / ACCESS Newswire / September 28, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its artificial intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, and Tollo Health, LLC ("Tollo"), a healthcare company commercializing proprietary medical foods and dietary supplements and, through TolloBio, developing biopharmaceutical candidates, today announced the launch of the Health Lives Here m

Interim Co-CEO to Discuss Growing Patient Desire to Own Health Data TAMPA, FL / ACCESS Newswire / September 25, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its artificial intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™,announced that its Interim Co-CEO Gerald Commissiong will present "What Patients Really Want" at this year's National Telehealth and Virtual Care Summit in Las Vegas on Monday, September 28, 2026 at 9:15am PT. Mr. Commissiong will discuss the growing desire by patients across the country to own their individual he

Updated Website Aligns with Pending Marketing Initiatives Following Recent Acquisition of Helomics CLIA-certified Laboratory and Litigation Settlement TAMPA, FL / ACCESS Newswire / September 21, 2026 / DataMEDS AI, Inc. (NASDAQ:MEDS) (the "Company" or "DataMEDS"), a Health IT company vertically integrating health data acquisition and transfer, today announced that it launched its new corporate website www.DataMedsAI.com.This change comes following the recent announcement that DataMEDS has acquired Helomics Corporation's artificial intelligence (AI) Cancer Diagnostics Lab from Axe Compute, and that the Company settled outstanding litigation that resulted in the extinguishment of ~$19 mi

TAMPA, FL / ACCESS Newswire / September 18, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its artificial intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™,today announced that it has settled litigation related to outstanding debt and receivables related to the May 11, 2023 Wellgistics, LLC Membership Purchase Interest Agreement (the "Settlement Agreement") that were previously carried on the Company's balance sheet as liabilities totaling of approximately $19 million. As part of the Settlement Agreement, the Company retired approximately

Acquisition Provides Operational Capital to Drive Health Lives Here Campaign and Expand Services into Cancer Management Acquisition Provides Operational Capital to Drive Health Lives Here Campaign and Expand Services into Cancer Management PITTSBURGH, PA / ACCESS Newswire / September 15, 2026 / DataMEDS AI, Inc. (NASDAQ:MEDS) ("DataMEDS"), a Health IT company vertically integrating health data acquisition and transfer, today announced that it completed the acquisition of artificial intelligence cancer diagnostics laboratory business Helomics Corporation ("Helomics") from Axe Compute Inc. (NASDAQ:AGPU) ("Axe Compute" or the "Company"), a neocloud AI infrastructure platform.Under the agr

PITTSBURGH, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Axe Compute Inc. (NASDAQ:AGPU) ("Axe Compute" or the "Company"), a neocloud AI infrastructure platform, today announced the sale of its legacy artificial intelligence cancer diagnostics laboratory business Helomics Corporation ("Helomics") to DataMEDS AI, Inc. (NASDAQ:MEDS) ("DataMEDS"), a Health IT company vertically integrating health data acquisition and transfer. Under the agreement, Axe Compute sold its wholly-owned subsidiary Helomics in exchange for common shares and common share equivalents of DataMEDS. This agreement provides Axe Compute with potential future returns from DataMEDS common stock while completing its transition to a pur

Leading Healthcare IT Company and Former NFL Players Will Work Together to Provide Rural Communities Access to Telehealth and Pharmacy-based Services Through Health Lives Here Mobile App Leading Healthcare IT Company and Former NFL Players Will Work Together to Provide Rural Communities Access to Telehealth and Pharmacy-based Services Through Health Lives Here Mobile App TAMPA, FL / ACCESS Newswire / September 8, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its artificial intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™,and Tollo

This version includes the correct image.50% off available online at www.TolloHealth.Shop and www.CorexaRx.comSoon to become available at Health Lives Here™ pharmacies and on Amazon.com TAMPA, FL / ACCESS Newswire / August 27, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), an integrated healthcare company leveraging its Health IT infrastructure and artificial intelligence platform EinsteinRx™ combined with blockchain-enabled smart contracts platform PharmacyChain™ to provide integrated solutions for the tokenization of pharmaceutical serialization and the compliant delivery of healthcare and monetization of health data, today announced the U.S. 'direct-

50% off available online at www.TolloHealth.Shop and www.CorexaRx.comSoon to become available at Health Lives Here™ pharmacies and on Amazon.com TAMPA, FL / ACCESS Newswire / August 27, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), an integrated healthcare company leveraging its Health IT infrastructure and artificial intelligence platform EinsteinRx™ combined with blockchain-enabled smart contracts platform PharmacyChain™ to provide integrated solutions for the tokenization of pharmaceutical serialization and the compliant delivery of healthcare and monetization of health data, today announced the U.S. 'direct-to consumer' (DTC) launch of medical foo

Revenues grew 14% reaching $1.779M in Q2/26, beating management projectionsCorporate name change from Wellgistics Health, Inc. to DataMeds AI, Inc. in July 2026, which led to stock symbol change from 'WGRX' to 'MEDS' on NASDAQ Capital Markets$6.5 million new funding in June 2026 provided capital to support corporate turnaroundPending transaction with Datavault AI, EOS Technology Holdings, Scilex Holdings and HealthBridge Associates to consolidate patent protected blockchain, biometrics and pharmaceutical-adjunct products intellectual properties to deliver the "Health Lives Here" consumer app, in partnership with NFL Alumni Health (NFLAH), to deliver an effective healthcare experience to pati

TAMPA, FL / ACCESS Newswire / August 14, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMEDS AI," "DataMEDS," or the "Company"), an integrated healthcare company leveraging its Health IT infrastructure and artificial intelligence platform EinsteinRx™ combined with blockchain-enabled smart contracts platform PharmacyChain™ to provide integrated solutions for the compliant delivery of healthcare and monetization of health data by market participants, today announced that its board of directors (the "Board") fixed September 9, 2026 (the "Payment Date") as the date on which the previously announced distribution (the "Distribution") of Dream Bowl Meme Coin I tokens (the "Dream Bowl Tokens") will be

GLP-1 agonist drugs now availableIntegration of online store CorexaRx.com into Health Lives Here app now completeMedical foods Forzet™ & Galectovid™, and dietary supplement Tollovid® now availableRevenue stabilized above $600,000 for July 2026 amid rebranding as pharmacy prepares to expand through the launch of Health Lives Here app with NFL Alumni Health TAMPA, FL / ACCESS Newswire / August 12, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), an integrated healthcare company leveraging its Health IT infrastructure and artificial intelligence platform EinsteinRx™ combined with blockchain-enabled smart contracts platform PharmacyChain™ to provide integrate

TAMPA, FL / ACCESS Newswire / August 10, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), a Health IT company leveraging its artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contracts platform PharmacyChain™ to provide integrated solutions for the compliant monetization of health data by market participants, today announced that it has completed the name changes of its pharmacy and pharmacy hub subsidiaries to Corexa Pharmacy, LLC ("Corexa Pharmacy") and Corexa Tech & Hub, LLC ("Corexa Hub"), respectively. Corexa Pharmacy and Corexa Hub are themselves subsidiaries of the Company's newly renamed pharmacy-focused division Corexa Hea

TAMPA, FL / ACCESS Newswire / August 6, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), a Health IT company leveraging its artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contracts platform PharmacyChain™ to provide integrated solutions for the compliant monetization of health data by market participants, today reiterated the August 7, 2026 record date for the 50:1 token to stock ratio for the Dream Bowl Meme Coin token (to DataMEDS common shares.The official platform for Dream Bowl Meme Coin tokens is https://www.biconomy.com/exchange/DREAM1_USDT. Dream Bowl Meme Coin token is not authorized to trade on CoinBase https://www.coi

Initiative with NFL Alumni Health is aimed at improving rural healthcare access by powering Health Lives Here consumer app that integrates Einstein AI with independent pharmacies and proprietary patient engagement tools TAMPA, FL / ACCESS Newswire / August 5, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," the "Company" or "DataMEDS"), a Health IT company leveraging its artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contracts platform PharmacyChain™ to provide integrated solutions for the compliant monetization of health data by market participants, today announced that Interim Co-CEO Gerald Commissiong will be featured with a marquee NFL Hall of Famer with

Launch targets acute viral infection and Long COVID markets through www.CorexaRx.com/Store TAMPA, FL / ACCESS Newswire / July 31, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI" or the "Company"), a Health IT company leveraging its artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contracts platform PharmacyChain™ to provide integrated solutions for the compliant monetization of health data by market participants, today announced that its wholly-owned online pharmacy, Corexa Pharmacy (www.CorexaRx.com/store), has begun direct-to-consumer (DTC) distribution of Tollovid®, a 3CL protease inhibitor dietary supplement, and Galactovid™, a medical food for the dietary

Data monetization and real-world asset tokenization technologies licensed into the DataMeds AI's EinsteinRX PlatformHealthcare data represents 30%+ of global data assets growing by 36% per annum; DVLT and MEDS patented technology platforms designed to value, score and monetize healthcare data TAMPA, FL / ACCESS Newswire / July 29, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMEDS"), a Health IT company leveraging its artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contacts platform PharmacyChain™ to provide integrated solutions for the generation, rationalization, intervention, transaction and monetization of health data and Datavault AI Inc. ("Datavault AI" or the